This was in the $3.90 range when the news hit last week on Thursday regarding the independent committee's report which many thought actually applied to the wrong drug. The response to the F.D.A. won't take place for several months. There is no urgency for the old shareholders to buy a stock which is falling back towards $3.00 - they'll wait until it bottoms in the $3.40 range. Also recent buyers on margin will be selling today or tomorrow. I sold my position yesterday and will buy back in at some point.